2023 was a tough yr for the biopharma industry, with many businesses downsizing and restructuring their workforces to stay afloat. There are actually indications of recovery, as mergers and acquisitions picked up across the pharmaceutical and existence sciences sector from the latter Element of 2023 and possess continued their upswing https://sites.google.com/view/bio-sites/blog